Corcept Therapeutics (CORT) Operating Leases (2019 - 2026)

Corcept Therapeutics has disclosed Operating Leases across 7 years of filings, most recently posting $9.6 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $9.6 million, up 40.99% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.6 million (up 40.99% YoY), and the FY2025 annual result was $5.0 million, down 17.75% from the prior year.
• Operating Leases came in at $9.6 million for Q1 2026 at Corcept Therapeutics, up from $5.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $9.6 million in Q1 2026 to a low of $76000.0 in Q1 2024.
• The 5-year median for Operating Leases is $3.9 million (2022), against an average of $3.8 million.
• Across the five-year window, Operating Leases tumbled 86.88% in 2023 and jumped 8893.42% in 2025, its largest moves.
• Corcept Therapeutics' Operating Leases stood at $1.1 million in 2022, then tumbled by 80.31% to $225000.0 in 2023, then surged by 2614.22% to $6.1 million in 2024, then declined by 17.75% to $5.0 million in 2025, then soared by 91.86% to $9.6 million in 2026.
• The last three Operating Leases figures came in at $9.6 million (Q1 2026), $5.0 million (Q4 2025), and $5.3 million (Q3 2025), per Business Quant data.